(MENAFN- GlobeNewsWire - Nasdaq) Opportunities span autoimmune and cancer therapies, ADCs and personalized medicine; AI design, rapid screening, predictive toxicity and biotech partnerships are key trends.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Preclinical Antibody Development Global Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Preclinical Antibody Development Market to Reach $7.93 Billion by 2030 as AI Adoption and Biologics Research Accelerate
The global preclinical antibody development market is experiencing rapid expansion, driven by growing demand for therapeutic antibodies and continued investment in biologics research. The market is projected to increase from $4.77 billion in 2025 to $5.27 billion in 2026, representing a compound annual growth rate (CAGR) of 10.5%. Historical growth has been supported by advances in monoclonal antibody technologies, expanding oncology and infectious disease research, improvements in laboratory automation, and higher research and development spending among pharmaceutical and biotechnology companies.
Strong growth is expected to continue through the end of the decade. The preclinical antibody development market is forecast to reach $7.93 billion in 2030, expanding at a CAGR of 10.7%. Key growth drivers include the adoption of artificial intelligence-based antibody design platforms, the integration of predictive analytics into preclinical studies, and the expansion of biotechnology research infrastructure. Increasing interest in personalized medicine and a growing number of collaborations between pharmaceutical companies, biotechnology firms, research organizations, and specialist service providers are also expected to strengthen market development.
Technological innovation is reshaping antibody discovery, optimization, and preclinical testing. Major preclinical antibody development market trends include high-throughput antibody screening, AI-driven candidate optimization, advanced in vitro assays, predictive toxicity modeling, and early-stage developability assessments. These capabilities can help research teams identify promising candidates more efficiently, evaluate safety and performance earlier, and reduce the risk of costly failures during later stages of drug development.
The rising prevalence of autoimmune diseases is expected to be a significant market growth driver during the forecast period. Genetic susceptibility, environmental and lifestyle factors, changes in immune-modulating exposures, and improved disease awareness and diagnostics are contributing to an increasing patient burden. This trend has created substantial unmet medical needs and encouraged pharmaceutical and biotechnology companies to intensify the development of targeted biologic therapies. Preclinical antibody programs support these efforts by enabling researchers to discover, screen, characterize, and optimize candidates designed to modulate dysregulated immune responses before clinical evaluation.
Recent data highlight the scale of the potential demand. In February 2024, Arthritis Australia reported projections indicating that approximately 212,136 males and 362,137 females would be living with rheumatoid arthritis in Australia in 2025. By 2040, those totals are projected to rise to about 280,040 males and 479,828 females. The increasing prevalence of chronic autoimmune conditions is therefore expected to generate sustained demand for innovative antibody therapies and the specialized preclinical services required to advance them.
Antibody-drug conjugates are also becoming an important area of innovation within the market, particularly for targeted cancer treatment. In November 2024, South Korea-based Celltrion Inc. announced the development of CT-P70 and CT-P71, two novel preclinical candidates targeting solid tumors, including non-small cell lung cancer and bladder cancer. The programs are designed to improve tumor targeting while reducing off-target toxicity. Their development reflects a wider industry transition toward differentiated biologic therapies with the potential to improve treatment efficacy and therapeutic outcomes.
Strategic acquisitions are further strengthening preclinical antibody development capabilities. In May 2024, Denmark-based biopharmaceutical company Genmab A/S acquired ProfoundBio for an undisclosed amount. The acquisition is intended to enhance Genmab's preclinical antibody development operations and accelerate its pipeline of innovative therapeutics. ProfoundBio focuses on antibody discovery and development for next-generation biologics, making the transaction strategically relevant to Genmab's broader research and development objectives.
North America was the largest region in the preclinical antibody development market in 2025, supported by established pharmaceutical and biotechnology industries, advanced research infrastructure, and significant investment in biologics. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The market analysis covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the UK, the USA, Canada, Italy, and Spain.
Markets Covered:
1) By Type: Monoclonal Antibodies; Polyclonal Antibodies; Other Types
2) By Service Type: Antibody Discovery; Humanization and Engineering; Affinity Maturation; Developability Assessment; Expression and Purification; In Vitro Functional Characterization
3) By Application: Oncology; Infectious Diseases; Autoimmune Diseases; Other Applications
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Murine Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies; Recombinant Monoclonal Antibodies
2) By Polyclonal Antibodies: Primary Polyclonal Antibodies; Secondary Polyclonal Antibodies; Affinity Purified Polyclonal Antibodies; Antiserum Polyclonal Antibodies; Species Specific Polyclonal Antibodies
3) By Other Types: Bispecific Antibodies; Single Domain Antibodies; Antibody Fragments; Conjugated Antibodies; Catalytic Antibodies
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment